Krystal Biotech (KRYS) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Krystal Biotech (KRYS) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Krystal Biotech | 9.84 Bn | 9.02 Bn | 110.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.86% |
| Dec 31, 2025 | -35.25% |
| Sep 30, 2025 | 106.81% |
| Jun 30, 2025 | 7.39% |
| Mar 31, 2025 | -21.43% |
| Dec 31, 2024 | 67.39% |
| Sep 30, 2024 | 74.52% |
| Jun 30, 2024 | 1,570.39% |
| Mar 31, 2024 | -89.28% |
| Dec 31, 2023 | -89.24% |
| Sep 30, 2023 | 343.14% |
| Jun 30, 2023 | 70.95% |
| Mar 31, 2023 | -235.98% |
| Dec 31, 2022 | 50.40% |
| Sep 30, 2022 | -19.41% |
| Jun 30, 2022 | 29.62% |
| Mar 31, 2022 | -270.58% |
| Dec 31, 2021 | 12.25% |
| Sep 30, 2021 | 36.06% |
| Jun 30, 2021 | 12.38% |